DAFTAR PUSTAKA

Abdel-Aziz, M. & Gamal-Eldeen, A.M. (2009) 'Synthesis and screening of anti-cancer, antioxidant, and anti-inflammatory activities of novel galloyl pyrazoline derivatives', *Pharmaceutical Biology*, 47(9), pp. 854–863. https://doi.org/10.1080/13880200902946452.

Adnin Tri Suma, A., Dwi Wahyuningsih, T. & Mustofa (2019) 'Synthesis, cytotoxicity evaluation and molecular docking study of n-phenylpyrazoline derivatives', *Indonesian Journal of Chemistry*, 19(4), pp. 1081–1090. https://doi.org/10.22146/ijc.45777.

Alatise, K.L., Gardner, S. & Alexander-Bryant, A. (2022) 'Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets', *Cancers*. MDPI. https://doi.org/10.3390/cancers14246246.

Armstrong, D.K., Alvarez, R., Bakkum-Gamez, J., Barroilhet, L., & Behbakht, K. (2021) 'Ovarian cancer, version 2.2020', *JNCCN Journal of the National Comprehensive Cancer Network*, 19(2), pp. 191–226. https://doi.org/10.6004/jnccn.2021.0007.

Berek, J.S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', *International Journal of Gynecology and Obstetrics*, 155(S1), pp. 61–85. https://doi.org/10.1002/ijgo.13878.

Bonello, M., Sims, A.H. & Langdon, S.P. (2018) 'Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer', *Cancer Biology and Medicine*. Cancer Biology and Medicine, pp. 375–388. https://doi.org/10.20892/j.issn.2095-3941.2018.0062.

Chunaifah, I., Venilita, R., Tjitda, P., Astuti, E., & Wahyuningsih, T. (2024) 'Thiophene-based N-phenyl pyrazolines: Synthesis, anticancer activity, molecular docking and ADME study', *Journal of Applied Pharmaceutical Science*, 14(4), pp. 63–71. https://doi.org/10.7324/JAPS.2024.146832.

Fu, D., Hu, Z., Xu, X., Dai, X., & Liu, Z. (2022) 'Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities', *Translational Oncology*, 26. https://doi.org/10.1016/j.tranon.2022.101510.

Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021) 'The mtt assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis', *International Journal of Molecular Sciences*, 22(23). https://doi.org/10.3390/ijms222312827.

Hallas-Potts, A., Dawson, J.C. & Herrington, C.S. (2019) 'Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas', *Scientific Reports*, 9(1). https://doi.org/10.1038/s41598-019-41941-4.

Huang, P., Xu, X., Wang, L., Zhu, B., Wang, X., & Xia, J. (2014) 'The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment', *Journal of Cellular and Molecular Medicine*, 18(2), pp. 218–230. https://doi.org/10.1111/jcmm.12153.

Iqbal, Nida and Iqbal, & Naveed (2014) 'Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications', *Molecular Biology International*, 2014, pp. 1–9. https://doi.org/10.1155/2014/852748.

Jaragh-Alhadad, L. (2018) 'In-vitro evaluation of HSP27 inhibitors function through HER2 pathway for ovarian cancer therapy', *Translational Cancer Research*, 7(6), pp. 1510–1517. https://doi.org/10.21037/tcr.2018.11.14.

Longuespée, R., Boyon, C., Desmons, A., Vinatier, D., & Leblanc, E. (2012) 'Ovarian cancer molecular pathology', *Cancer and Metastasis Reviews*, 31(3–4), pp. 713–732. https://doi.org/10.1007/s10555-012-9383-7.

Luo, H., Xu, X., Ye, M., Sheng, B., & Zhu, X. (2018) 'The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies', *PLoS ONE*, 13(1). https://doi.org/10.1371/journal.pone.0191972.

Matiadis, D. & Sagnou, M. (2020) 'Pyrazoline hybrids as promising anticancer agents: An up-to-date overview', *International Journal of Molecular Sciences*. MDPI, pp. 1–41. https://doi.org/10.3390/ijms21155507.

Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) 'Ovarian cancer in the world: Epidemiology and risk factors', *International Journal of Women's Health*. Dove Medical Press Ltd, pp. 287–299. https://doi.org/10.2147/IJWH.S197604.

Schroeder, R.L., Stevens, C.L. & Sridhar, J. (2014) 'Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer', *Molecules*. MDPI AG, pp. 15196–15212. Available at: https://doi.org/10.3390/molecules190915196.

Sever, R. & Brugge, J.S. (2015) 'Signal transduction in cancer', *Cold Spring Harbor Perspectives in Medicine*, 5(4). https://doi.org/10.1101/cshperspect.a006098.

Sohrab, S.S. & Kamal, M.A. (2022) 'Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer', *Life*, 12(11). https://doi.org/10.3390/life12111729.

Teplinsky, E. & Muggia, F. (2015) 'EGFR and HER2: Is there a role in ovarian cancer?', *Translational Cancer Research*. AME Publishing Company, pp. 107–117. https://doi.org/10.3978/j.issn.2218-676X.2015.01.01.

Thouvenin, L., Charrier, M., Clement, S., Christinat, Y., & Tille, J. (2021) 'Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab', *Gynecologic Oncology Reports*, 37, p. 100787. https://doi.org/10.1016/j.gore.2021.100787.

Torre, L.A., Trabert, B., De Santis, C., Miller, K., Samimi, G., & Runowicz, C. (2018) 'Ovarian cancer statistics, 2018', *CA: A Cancer Journal for Clinicians*, 68(4), pp. 284–296. https://doi.org/10.3322/caac.21456.

Toss, A., De Matteis, E., Rossi, E., Casa, L., Iannone, E., Federico, M., & Cortesi, L. (2013) 'Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?', *International Journal of Molecular Sciences*, 14(4), pp. 8271–8290. https://doi.org/10.3390/ijms14048271.

Wang, H., Jiang, Y., Jin, H., & Wang, C. (2022) 'ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients', *Frontiers in Oncology*, 12. https://doi.org/10.3389/fonc.2022.1012138.

Wang, W., Gao, Y., Hai, J., Yang, J., & Duan, S. (2019) 'HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way', *Bioscience Reports*, 39(3). https://doi.org/10.1042/BSR20180829.

Widiandani, T., Tandian, T., Zufar, B., Suryadi, A., Purwanto, B., Hardjono, S., & Siswandono (2023) 'In vitro study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index', *Journal of Public Health in Africa*, 14(S1). https://doi.org/10.4081/jphia.2023.2516.

Xu, W., Pan, Y., Wang, H., Li, H., Peng, Q., Wei, D., Chen, C., & Zheng, J. (2017) 'Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents in HepG-2 cell line', *Molecules*, 22(3). https://doi.org/10.3390/molecules22030467.

Zamwar, U.M. & Anjankar, A.P. (2022) 'Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer', *Cureus* [Preprint]. https://doi.org/10.7759/cureus.30561.